Pharsight

Vyndaqel generic

Vyndaqel is a drug owned by Foldrx Pharms. Its active ingredient is tafamidis meglumine. The drug was first authorised for market use on 03 May, 2019 and it currently holds 4 patents, out of which 2 have expired. Vyndaqel comes in a capsule;oral dosage form.

When will Vyndaqel generic be available?

The generic versions of Vyndaqel could potentially be released after 03 May, 2026, once all the patents expire. Patent challenges for Vyndaqel could commence from 2023-05-04. The last patent to expire appears to be 'Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding', US7214695, which will expire on 2024-12-19.

Vyndaqel uses

Vyndaqel, which contains tafamidis meglumine, is utilized for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm). The active ingredient, tafamidis meglumine, functions effectively to manage the condition.

Vyndaqel patent expiration

Vyndaqel, whose generic may be released post 03 May, 2026, holds 4 patents. Two of the key patents are 'Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding', US7214695, and 'Methods for treating transthyretin amyloid diseases', US8653119, expiring on 24 December, 2024 and 19 December, 2023 respectively. Below are the details of the patent:

Vyndaqel dosage

Want to ask something?